ATE512671T1 - Verwendung von antikörpern gegen den lamininrezeptor oder den lamininrezeptorvorläufer zur diagnose von krebs - Google Patents

Verwendung von antikörpern gegen den lamininrezeptor oder den lamininrezeptorvorläufer zur diagnose von krebs

Info

Publication number: ATE512671T1
Authority: AT; Austria
Prior art keywords: laminin receptor; diagnostics; antibodies; cancer; precursor
Prior art date: 2005-04-05

Application number

AT05007380T

Other languages

English (en)

Inventor

Melvyn Little

Stefan Knackmuss

Uwe Reusch

Sergey Kipriyanov

Gall Fabrice Le

Vera Mick

Karin Hoffmann

Peter Roettgen

Stefan Weiss

Original Assignee

Affimed Therapeutics Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-05

Filing date

2005-04-05

Publication date

2011-07-15

2005-04-05 Application filed by Affimed Therapeutics Ag filed Critical Affimed Therapeutics Ag

2011-07-15 Application granted granted Critical

2011-07-15 Publication of ATE512671T1 publication Critical patent/ATE512671T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Hematology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT05007380T 2005-04-05 2005-04-05 Verwendung von antikörpern gegen den lamininrezeptor oder den lamininrezeptorvorläufer zur diagnose von krebs ATE512671T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP05007380A EP1709972B1 (de)	2005-04-05	2005-04-05	Verwendung von Antikörpern gegen den Lamininrezeptor oder den Lamininrezeptorvorläufer zur Diagnose von Krebs

Publications (1)

Publication Number	Publication Date
ATE512671T1 true ATE512671T1 (de)	2011-07-15

Family

ID=34979018

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05007380T ATE512671T1 (de)	2005-04-05	2005-04-05	Verwendung von antikörpern gegen den lamininrezeptor oder den lamininrezeptorvorläufer zur diagnose von krebs

Country Status (6)

Country	Link
US (1)	US7901677B1 (de)
EP (1)	EP1709972B1 (de)
AT (1)	ATE512671T1 (de)
AU (1)	AU2006232836B2 (de)
CA (1)	CA2603480A1 (de)
WO (1)	WO2006105954A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008115601A1 (en) *	2007-03-22	2008-09-25	The Johns Hopkins University	67lr antibodies and their uses in the treatment of cancer
DE102007041834A1 (de) *	2007-09-03	2009-03-05	Siemens Ag	Arzneimittel zur Behandlung eines Karzinoms
WO2017118761A1 (en) *	2016-01-08	2017-07-13	Iontas Ltd	Binding members with altered diversity scaffold domains
GB201711208D0 (en)	2017-07-12	2017-08-23	Iontas Ltd	Ion channel inhibitors
US12679903B2 (en) *	2018-09-17	2026-07-14	Zymedi Co., Ltd.	Antibody for specifically binding to lysyl-tRNA synthetase N-terminal domain exposed to extracellular membrane

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5637481A (en) *	1993-02-01	1997-06-10	Bristol-Myers Squibb Company	Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US7442776B2 (en) *	1999-10-08	2008-10-28	Young David S F	Cancerous disease modifying antibodies
US7419792B2 (en) *	1999-10-08	2008-09-02	Arius Research Inc.	Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
WO2003032813A2 (en) *	2001-10-18	2003-04-24	Genentech Inc.	Methods for the treatment of carcinoma
DE10346627A1 (de) *	2003-10-08	2005-05-19	Weiss, Stefan, PD Dr.	Single-chain-Antikörper gegen den 37 kDa/67 kDa Lamininrezeptor als Werkzeuge zur Diagnose und Therapie von Prionerkrankungen und Krebs, deren Herstellung und Verwendung

2005
- 2005-04-05 AT AT05007380T patent/ATE512671T1/de not_active IP Right Cessation
- 2005-04-05 EP EP05007380A patent/EP1709972B1/de not_active Expired - Lifetime
2006
- 2006-04-05 CA CA002603480A patent/CA2603480A1/en not_active Abandoned
- 2006-04-05 AU AU2006232836A patent/AU2006232836B2/en not_active Ceased
- 2006-04-05 WO PCT/EP2006/003104 patent/WO2006105954A2/en not_active Ceased
- 2006-04-05 US US11/910,478 patent/US7901677B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7901677B1 (en)	2011-03-08
AU2006232836A1 (en)	2006-10-12
EP1709972B1 (de)	2011-06-15
AU2006232836B2 (en)	2012-05-31
EP1709972A1 (de)	2006-10-11
CA2603480A1 (en)	2006-10-12
WO2006105954A3 (en)	2007-01-18
WO2006105954A2 (en)	2006-10-12

Similar Documents

Publication	Publication Date	Title
DK1565489T3 (da)	2011-03-07	Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
ATE509033T1 (de)	2011-05-15	Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
EA201001874A1 (ru)	2011-08-30	Способ диагностики злокачественных новообразований, экспрессирующих рецептор her2 или его укороченные варианты
CY1118880T1 (el)	2018-01-10	Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NZ603492A (en)	2014-05-30	Humanized anti-factor d antibodies and uses thereof
BRPI0711908B8 (pt)	2021-05-25	anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo.
IL212056A0 (en)	2011-06-30	Monoclonal antibodies and methods for their use in the detection of cervical disease
ATE502052T1 (de)	2011-04-15	Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii)
EP2210939A4 (de)	2012-08-08	Anti-bst2-antikörper
ATE441116T1 (de)	2009-09-15	Verfahren zur selektiven bestimmung von procalcitonin 1-116 für diagnostische zwecke sowie antikírper und kits zur ausführung dieses verfahrens
DE60130538D1 (de)	2007-10-31	Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
EA200701292A1 (ru)	2008-06-30	Композиции, содержащие антитела против рецептора igf-1, и способы получения антител
EP2010911A4 (de)	2009-05-13	Behandlung von egf-rezeptormutanten exprimierenden tumoren
BR112012009846B8 (pt)	2021-05-25	método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige
BRPI0914925A2 (pt)	2015-10-20	peptídeo cíclico, uso de um peptídeo, métodos para produzir um peptídeo cíclico e para diagnosticar uma doença ou condição, e, anticorpo
ATE474857T1 (de)	2010-08-15	Antikörper gegen ein epitop auf agr2, assays und hybridome
WO2011064257A3 (de)	2011-08-11	Monospezifische polypeptidreagenzien
BRPI1005176A2 (pt)	2016-12-06	ensaio de insulina, reagente de ensaio de insulina, anticorpo monoclonal, e, método de triar anticorpos monoclonais.
EA202091569A1 (ru)	2021-02-11	Моноклональные антитела и способы их применения
MX2023004212A (es)	2023-09-06	Conjugados reactivos.
WO2012170929A3 (en)	2013-04-25	Monoclonal antibody and antigens for diagnosing and treating lung disease and injury
EA200701092A1 (ru)	2008-02-28	Антигенные эпитопы интерлейкина-21, связанные с ними антитела и их применение в медицине
FI3356826T3 (fi)	2024-01-08	Gdf-15 melanooman diagnostisena markkerina
WO2010053772A3 (en)	2011-02-24	Disease-associated antigens and methods of use thereof
FI20012603A0 (fi)	2001-12-31	Diagnostinen menetelmä

Legal Events

Date	Code	Title	Description
2011-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties